December 16, 2019
1 min read

Companies collaborate on technology to improve sepsis care

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Ontera CEO Murielle Thinard-McLane
Murielle Thinard-McLane

Ontera and QuantuMDx announced that they will collaborate on a technology to quickly detect bloodstream infections and drug resistance, with an aim toward improving outcomes for patients with sepsis.

“Both Ontera and QuantuMDx are continually evaluating disease areas where there is a great need for improved diagnostic tools,” Ontera CEO Murielle Thinard-McLane told Healio. “Ontera and QuantuMDx each offer unique technologies to improve the diagnosis of a wide variety of conditions, and the companies recognized an opportunity to unite the power of their technologies to improve sepsis diagnosis through a global research collaboration.”

According to a news release, QuantuMDx’s rapid cell/sample preparation technology (Capture-XT) and Ontera’s nanopore biosensor will be the foundation for the new technology, which will allow for rapid testing of samples taken from patients with suspected sepsis.

“Our early prototype testing has already shown sensitivity in the range required for this kind of test and performed in minutes from spiked bacteria in whole blood. We haven’t even pushed the technology yet, but it has the potential to become a paradigm-shifting, powerful device,” QuantuMDx Chief Scientific Officer Jonathan O’Halloran, PhD, said in the release. “And, by including drug resistance in the assay to enable right first time prescribing, the impact of this partnership could be profound.”

Globally, more than 30 million people are diagnosed with sepsis each year and approximately 6 million die as a result, according to WHO.

To be effectively treated, sepsis must be diagnosed correctly and quickly so that treatment and management are appropriate. Incorrect diagnosis or management could result in septic shock, multiple organ failure and death, the companies noted. They suggested that the new technology will be able to test samples rapidly at the bedside “allowing guided ‘right first time’ care management.”

“Traditional sepsis diagnostic methods involve 24-hour culture in a lab, with a further processing period required for drug resistance analysis,” Thinard-McLane noted. “As sepsis can become life threatening in a very short period of time, clinicians need to act fast. Together, the QuantuMDx and Ontera platform aims to deliver comprehensive test results in less than 30 minutes at the point of care.” – by Marley Ghizzone

Disclosures: O’Halloran is employed by QuantuMDx. Thinard-McLane is employed by Ontera.